The European Commission has withdrawn the regulatory authorization granted for Viatris (NASDAQ:VTRS) to market arsenic trioxide, a generic version of a cancer medicine marketed by Teva Pharmaceutical (NYSE:TEVA) as Trisenox, according to an update from the European Medicines
